Characteristics | Patients (n = 8064) |
---|---|
Sex, n (%) | |
 Male | 4578 (56.8) |
 Female | 3486 (43.2) |
Age, years, median (Q1–Q3) | 70 (61–78) |
 ≤ 17 years | 17 (0.2) |
 18–64 years | 2624 (32.5) |
 65–74 years | 2504 (31.0) |
 ≥ 75 years | 2919 (36.2) |
Underlying disease, n (%) | |
 Hodgkin lymphoma | 199 (2.5) |
 non-Hodgkin lymphoma | 4028 (50.0) |
 Multiple myeloma | 1153 (14.3) |
 Lymphoid leukaemia | 551 (6.8) |
 Myeloid leukaemia | 1224 (15.2) |
 Myelodysplastic syndromes | 909 (11.3) |
CCI, n (%) | |
 ≤ 2 | 6394 (79.3) |
 3–5 | 1392 (17.3) |
 > 5 | 278 (3.4) |
Follow-up duration, days, median (Q1–Q3) | 97 (26–227) |
Total LOS, days, median (Q1–Q3) | 50 (22–107) |
LOS at one hospitalization, days, median (Q1–Q3) | 19 (10–30) |
Chemotherapy, n (%) | 6542 (81.1) |
Febrile neutropenia, n (%) | 1100 (13.6) |
G-CSF, n (%) | 4039 (50.1) |
Central venous catheter, n (%) | 3072 (38.1) |
Urinary catheter, n (%) | 2109 (26.2) |
HSCT, n (%) | |
 Allogeneic | 407 (5.0) |
 Autologous | 301 (3.7) |
 Isolation room, n (%) | 2352 (29.2) |
 In-hospital mortality, n (%) | 1761 (21.8) |